Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is a chronic, heterogeneous, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. SLE predominantly affects young, middle-aged, and child-bearing women with episodes of flare-up and remission, although it affects males at a much lower frequency (female: male; 7:1 to 15:1). Technological and molecular advancements have helped in patient stratification and improved patient prognosis, morbidity, and treatment regimens overall, impacting quality of life.

Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.

While considerable information exists on the ten-eleven translocation 2 (TET2) mutational landscape in AML, the information on expression is limiting. So, we aimed to study the expression at mRNA and protein levels in AML patients compared to healthy controls. To achieve this, we recruited 70 non-M3, de novo AML patients and 20 healthy controls.